
Loading, please wait...

Loading, please wait...

People living with HIV (PLWH) face a significantly higher risk for allograft rejection after receiving a kidney transplant. While this risk is well-documented, the underlying biological mechanisms remain somewhat elusive. Some researchers have suggested that immune dysregulation and chronic inflammation, driven by HIV latency, might play a role. A new study by Sulaiman A et al. recently explored the connection between the HIV reservoir transplant rejection risk and clinical outcomes in these patients.
In this investigation, the research team focused on kidney transplant recipients who received organs from both HIV-positive and HIV-negative donors. They specifically looked at the latent viral reservoir (LVR) size at baseline and through 52 weeks post-transplant. To measure the reservoir accurately, they utilized the advanced intact proviral DNA assay. Consequently, they compared the LVR levels between participants who experienced rejection and those who did not.
The results were quite revealing for the transplant community. Surprisingly, the researchers found no significant differences in the size of the latent reservoir between the two groups. This lack of difference held true regardless of the donor's HIV status. Therefore, the presence or size of the latent virus does not seem to be the primary driver of acute rejection episodes in this population.
These findings provide essential evidence supporting the feasibility of organ transplantation between HIV-positive individuals. Furthermore, the study suggests that the increased rejection risk in PLWH likely stems from other factors. These factors may include complex interactions with immunosuppressive medications or specific T-cell responses. Physicians can now feel more confident in the safety profiles of donor-positive transplants regarding viral reservoir dynamics.
Clinicians should continue to monitor kidney transplant recipients with HIV closely for rejection. However, they can take reassurance from the fact that the latent reservoir size does not appear to correlate with rejection risk. As we expand the use of the HOPE Act protocols, these biological insights remain vital for optimizing patient management and long-term graft survival.
No, recent research indicates there is no significant difference in the latent HIV reservoir size between patients who experience rejection and those who do not.
Yes, data from the latest studies support the feasibility and safety of HIV+ to HIV+ organ transplantation, showing no negative impact related to the viral reservoir.
The study used the intact proviral DNA assay to evaluate the reservoir size at baseline and up to one year after the transplant procedure.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
1. Sulaiman A et al. Allograft Rejection and the Latent HIV Reservoir in Kidney Transplant Recipients with HIV. J Infect Dis. 2026 Mar 13. doi: undefined. PMID: 41823991.
2. Glicklich D, Nog R. HIV in kidney transplantation. Curr Opin Organ Transplant. 2022 Feb 1;27(1):65-71.
3. Durand CM et al. Safety of Kidney Transplantation from Donors with HIV. N Engl J Med. 2024 Oct 17;391(15):1390-1401.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New research finds no link between latent HIV reservoir size and kidney transplant rejection, supporting the feasibility of HIV+ to HIV+ organ donation....
5 months ago

Personalized medicine requires novel reimbursement models. This review examines how indication-based and performance-based pricing schemes influence drug availability, patient equity, and health system sustainability across multi-indication therapies.
Today

A retrospective cohort study reveals that simulation-free vaginal cuff brachytherapy achieves low 5-year vaginal recurrence rates comparable to simulation-verified protocols in high-intermediate risk endometrial cancer, supporting streamlined radiation oncology workflows.
Today

A systematic review evaluates machine learning models predicting cardiovascular adverse events in cancer patients, highlighting XGBoost performance, calibration gaps, and validation needs.
Today

A breakthrough study reveals how the agricultural fungicide thiram disrupts hepatic and tibial calcium homeostasis through ER stress and IP3R1/VDAC1 hyperactivation, uncovering a critical liver-bone axis of systemic toxicity.
Today

A study in children with severe acute malnutrition reveals disordered pancreatic and gut hormone responses to nutrient stimulation, including elevated basal insulin and blunted postprandial surges. These findings emphasize the need for refined nutritional rehabilitation protocols to prevent metabolic complications.
Today